What a string of semaglutide biosimilars could mean for Mainland China
Clarivate
MAY 14, 2024
However, availability of cost-effective biosimilars of semaglutide starting 2026 is likely to influence patient perception of the drug in a price-sensitive Chinese market, especially for obese patients in the absence of reimbursement for weight loss drugs.
Let's personalize your content